Synthesis and biological activity of DNA damaging agents that form decoy binding sites for the estrogen receptor.
暂无分享,去创建一个
[1] J. Sambrook,et al. Molecular Cloning: A Laboratory Manual , 2001 .
[2] S. Lippard,et al. The HMG-domain protein Ixr1 blocks excision repair of cisplatin-DNA adducts in yeast. , 1996, Mutation research.
[3] G. Eisenbrand,et al. Synthesis of novel androgen-linked phosphoramide mustard prodrugs and growth-inhibitory activity in human breast cancer cells. , 1995, Anti-cancer drug design.
[4] D. Crothers,et al. Interaction of human immunodeficiency virus type 1 Tat-derived peptides with TAR RNA. , 1995, Biochemistry.
[5] B. Katzenellenbogen,et al. Antiestrogens: Mechanisms and actions in target cells , 1995, The Journal of Steroid Biochemistry and Molecular Biology.
[6] K. Powell,et al. Binding of the transcription factor, Sp1, to non-target sites in DNA modified by benzo[a]pyrene diol epoxide. , 1995, Carcinogenesis.
[7] G. Chu,et al. A novel role for DNA photolyase: binding to DNA damaged by drugs is associated with enhanced cytotoxicity in Saccharomyces cerevisiae. , 1994, Molecular and cellular biology.
[8] S. Lippard,et al. HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[9] D. K. Treiber,et al. Cisplatin-DNA adducts are molecular decoys for the ribosomal RNA transcription factor hUBF (human upstream binding factor). , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[10] S R Cherry,et al. An unnatural biopolymer. , 1993, Science.
[11] R. Tarone,et al. Platinum-DNA adduct in leukocyte DNA of a cohort of 49 patients with 24 different types of malignancies. , 1993, Cancer research.
[12] S. Lippard,et al. Ixr1, a yeast protein that binds to platinated DNA and confers sensitivity to cisplatin. , 1993, Science.
[13] J. Van De Sande,et al. Uracil-DNA glycosylase as a probe for protein--DNA interactions. , 1993, Nucleic acids research.
[14] L. McLaughlin,et al. Covalent structure of a nitrogen mustard-induced DNA interstrand cross-link: an N7-to-N7 linkage of deoxyguanosine residues at the duplex sequence 5'-d(GNC) , 1993 .
[15] S. Lippard,et al. Specific binding of chromosomal protein HMG1 to DNA damaged by the anticancer drug cisplatin. , 1992, Science.
[16] Masahiko S. Satoh,et al. Role of poly(ADP-ribose) formation in DNA repair , 1992, Nature.
[17] D. Housman,et al. Isolation and characterization of human cDNA clones encoding a high mobility group box protein that recognizes structural distortions to DNA caused by binding of the anticancer agent cisplatin. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[18] W. Denny,et al. DNA-directed alkylating agents. 3. Structure-activity relationships for acridine-linked aniline mustards: consequences of varying the length of the linker chain. , 1990, Journal of medicinal chemistry.
[19] D. K. Treiber,et al. Characterization of a DNA damage-recognition protein from mammalian cells that binds specifically to intrastrand d(GpG) and d(ApG) DNA adducts of the anticancer drug cisplatin. , 1990, Biochemistry.
[20] R. Pieper,et al. Transcription-terminating lesions induced by bifunctional alkylating agents in vitro. , 1989, Carcinogenesis.
[21] P. Chambon,et al. The cloned human oestrogen receptor contains a mutation which alters its hormone binding properties. , 1989, The EMBO journal.
[22] R. Evans,et al. The steroid and thyroid hormone receptor superfamily. , 1988, Science.
[23] B. Slotman,et al. Ovarian cancer (review). Etiology, diagnosis, prognosis, surgery, radiotherapy, chemotherapy and endocrine therapy. , 1988, Anticancer research.
[24] G. Goldenberg,et al. Estrogen receptor-binding affinity and cytotoxic activity of three new estrogen-nitrosourea conjugates in human breast cancer cell lines in vitro. , 1987, Cancer treatment reports.
[25] V. Jordan,et al. Structure-activity relationships of estrogens. , 1985, Environmental health perspectives.
[26] E von Angerer,et al. 2-Phenylindoles. Relationship between structure, estrogen receptor affinity, and mammary tumor inhibiting activity in the rat. , 1984, Journal of medicinal chemistry.
[27] W. Schuette,et al. Influence of cell proliferation and cell cycle phase on expression of estrogen receptor in MCF-7 breast cancer cells. , 1984, Cancer research.
[28] A. Riggs,et al. Lac repressor binding to non-operator DNA: detailed studies and a comparison of eequilibrium and rate competition methods. , 1972, Journal of molecular biology.
[29] S. Korenman. Relation Between Estrogen Inhibitory Activity and Binding to Cytosol of Rabbit and Human Uterus , 1970 .
[30] M. Fernö,et al. Estrogen and Progesterone Receptor Analyses in More Than 4000 Human Breast Cancer Samples: A Study with Special Reference to Age at diagnosis and stability of analyses , 1990 .
[31] H. Sambrook. Molecular cloning : a laboratory manual. Cold Spring Harbor, NY , 1989 .
[32] W. Gilbert,et al. Sequencing end-labeled DNA with base-specific chemical cleavages. , 1980, Methods in enzymology.
[33] B. Singer. The chemical effects of nucleic acid alkylation and their relation to mutagenesis and carcinogenesis. , 1975, Progress in nucleic acid research and molecular biology.
[34] Lawley Pd. Effects of Some Chemical Mutagens and Carcinogens on Nucleic Acids , 1966 .